Endo International (ENDP) Upgraded by Canaccord Genuity to “Buy”

Share on StockTwits

Canaccord Genuity upgraded shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a hold rating to a buy rating in a research report report published on Friday, MarketBeat Ratings reports. They currently have $20.00 price target on the stock, up from their previous price target of $16.00.

Several other analysts also recently weighed in on the company. Royal Bank of Canada upgraded Endo International from a sector perform rating to an outperform rating and set a $26.00 price objective for the company in a research report on Monday, August 13th. Zacks Investment Research upgraded Endo International from a hold rating to a buy rating and set a $18.00 price objective for the company in a research report on Monday, September 24th. Goldman Sachs Group upgraded Endo International from a sell rating to a neutral rating and boosted their price objective for the company from $14.00 to $15.00 in a research report on Tuesday, September 11th. TheStreet upgraded Endo International from a d rating to a c- rating in a research report on Monday, August 20th. Finally, BidaskClub downgraded Endo International from a strong-buy rating to a buy rating in a research report on Saturday, September 8th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $14.97.

NASDAQ:ENDP traded up $0.30 during mid-day trading on Friday, reaching $13.49. The stock had a trading volume of 6,440,068 shares, compared to its average volume of 4,723,015. The company has a market capitalization of $3.59 billion, a price-to-earnings ratio of 3.51, a PEG ratio of 1.54 and a beta of 0.65. Endo International has a one year low of $5.27 and a one year high of $18.50.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Thursday, November 8th. The company reported $0.71 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.12. The company had revenue of $745.00 million during the quarter, compared to the consensus estimate of $694.93 million. Endo International had a positive return on equity of 237.45% and a negative net margin of 34.72%. Endo International’s quarterly revenue was down 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS. On average, research analysts anticipate that Endo International will post 2.68 EPS for the current fiscal year.

In related news, Director Roger H. Kimmel sold 26,074 shares of the company’s stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $15.90, for a total transaction of $414,576.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.80% of the stock is owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the stock. Schroder Investment Management Group grew its stake in Endo International by 78.1% in the second quarter. Schroder Investment Management Group now owns 747,571 shares of the company’s stock worth $7,349,000 after purchasing an additional 327,775 shares during the period. Bank of New York Mellon Corp grew its stake in Endo International by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 2,446,852 shares of the company’s stock worth $23,074,000 after purchasing an additional 284,599 shares during the period. Sivik Global Healthcare LLC purchased a new stake in Endo International in the second quarter worth $1,697,000. Arizona State Retirement System grew its stake in Endo International by 115.7% in the second quarter. Arizona State Retirement System now owns 293,200 shares of the company’s stock worth $2,765,000 after purchasing an additional 157,252 shares during the period. Finally, Capital Growth Management LP purchased a new stake in Endo International in the third quarter worth $2,356,000. Institutional investors own 98.43% of the company’s stock.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Recommended Story: Calculate Your Return on Investment (ROI)

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply